Golfer247 - The latest news and products from the world of golf
Main Menu | News By Date | News By Supplier | News By Category | About Us
 

NEW CANCER-FIGHTING DRUGS POSSIBLE THROUGH STUDIES AT ARGONNE
16 May 2005 - DOE/Argonne National Laboratory

Proteins that could lead to drugs that stop tumor growth and cancer have been identified by biologists studying capillary formation, or angiogenesis, at the U.S. Department of Energy's Argonne National Laboratory.

Argonne researchers are the first to study the earliest steps in capillary formation in tumors. They identified 280 proteins that endothelial cells, cells that form blood vessels, secrete in large quantities during capillary growth. Because proteins are responsible for cellular structure and communication, biologists want to learn which ones to block to develop a treatment that arrests tumor growth by halting angiogenesis.

While anti-angiogenic drugs have shown promise in laboratory studies, they have not fared well in clinical trials. That is because they have targeted only individual molecular pathways, Argonne biologist Diane Rodi explains. Researchers expect their in-depth angiogenesis work to find more effective treatments.

Current cancer therapies attack fast-dividing cells such as hair follicles and the cells that line the gastrointestinal tract, causing side effects of nausea and hair loss.

"There is not a lot of capillary growth in normal adults. Humans only grow capillaries when healing from an injury or during menstrual cycles," says Rodi. "So if we can come up with a cocktail of drugs to knock out all capillary formation in the body, it might be a method of treating cancer patients that does not make them sick."

Capillaries are a tumor's lifeline, delivering oxygen to and removing waste from it. Tumors use capillaries to metastasize, or spread to other body tissues. When malignant tumors move to other body tissues, they disable tissue function.

"Tumors kill by invading the body's normal tissues and crowding them out, preventing them from doing their job," says Rodi. "A patient dies because those tissues cannot function properly."

Capillaries are formed by endothelial cells that form little hollow tubes. When a tumor lacks oxygen, it sends protein signals toward existing capillaries. Endothelial cells break off, releasing enzymes that chew through body tissue toward the tumor to make new capillaries.

Argonne's Angiogenesis Group mimics natural capillary formation. Endothelial cells that have been isolated from human tissue and mixed with growth factors are placed in a protein gel. The gel acts like body tissue and causes the cells to release enzymes.

Using a light microscope attached to a digital camera, the group takes snapshots of the cells and isolates their ribonucleic acid during the eight-hour capillary formation process.

The biologists identify the isolated RNA and, since RNA codes for proteins, determine what proteins the cells are making at each time interval.

http://www.anl.gov

About: DOE/Argonne National Laboratory
Argonne National Laboratory is one of the US Department of Energy's largest research centres. It is also the nation's first national laboratory, chartered in 1946.

Argonne is a direct descendant of the University of Chicago's Metallurgical Laboratory, part of the World War Two Manhattan Project. After the war, Argonne was given the mission of developing nuclear reactors for peaceful purposes. Over the years, Argonne's research expanded to include many other areas of science, engineering and technology.

Today, the laboratory has about 4000 employees, including about 1200 scientists and engineers, of whom about 700 hold doctorate degrees.

Argonne occupies two sites. The Illinois site is surrounded by forest preserve about 25 miles southwest of Chicago's Loop. About 3200 of Argonne's 4000 employees work on the site's 1500 wooded acres. The site also houses the US Department of Energy's Chicago Operations Office.

Argonne-West occupies about 900 acres about 50 miles west of Idaho Falls in the Snake River Valley. It is the home of most of Argonne's major nuclear reactor research facilities. About 800 of Argonne's employees work there.


More News:
  • For May 2005
  • From DOE/Argonne National Laboratory
  • For National Laboratory

 

©2008 New Materials International